Delay Differential Model for Tumour-Immune Response with Chemoimmunotherapy and Optimal Control

Abstract

We present a delay differential model with optimal control that describes the interactions of the tumour cells and immune response cells with external therapy. The intracellular delay is incorporated into the model to justify the time required to stimulate the effector cells. The optimal control variables are incorporated to identify the best treatment strategy with minimum side effects by blocking the production of new tumour cells and keeping the number of normal cells above 75% of its carrying capacity. Existence of the optimal control pair and optimality system are established. Pontryagin's maximum principle is applicable to characterize the optimal controls. The model displays a tumour-free steady state and up to three coexisting steady states. The numerical results show that the optimal treatment strategies reduce the tumour cells load and increase the effector cells after a few days of therapy. The performance of combination therapy protocol of immunochemotherapy is better than the standard protocol of chemotherapy alone.

Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma

“…Response or stable disease in mRCC may be preceded by apparent early disease progression, as has been seen in melanoma patients treated with ipilimumab (12). At this point, it is not clear whether a minimum amount of time is required to assess treatment response with anti-PD-1/PD-L1 therapy (13) or whether this new form of immunotherapy should be given continuously until progression or intermittently. Understanding the kinetics of response to immunecheckpoint inhibitors will help to improve the outcome of patients treated with anti-PD-1/PD-L1 therapies.…”

A mathematical model for chemoimmunotherapy of chronic lymphocytic leukemia

“…The current trend of use of chemoimmunotherapy in cancer research in general [26] has boosted several studies on mathematical oncology (e.g. [27,28,29,30]). In a practical sense, chemoimmunotherapy is becoming more and more a need for successful CLL treatments [31], but only a few studies are aimed at modeling (e.g.…”

A fractional-order delay differential model with optimal control for cancer treatment based on synergy between anti-angiogenic and immune cell therapies

“…Moreover, it has become an essential tool that is used to simulate tumor-immune cell interactions and to predict the therapeutic effect of various cancer treatments ( [2], [13], [15], [19], [23], [30], [39], [45]). Mathematical models, based on ordinary differential equations, delay differential equations, partial differential equations, have proven to be useful tools in analysing and understanding the interactions with viral, bacterial infections and cancerous cells [31]- [33].…”